[Suppressive effect of oxatomide on the induction of IL2 responsiveness by DF-stimulated lymphocytes from patients with bronchial asthma].
Oxatomide is an anti-allergic agent having an anti-histamine effect, and has been widely used for clinical purposes. The effect of oxatomide-treatment on the induction of IL2 responsiveness by Df-stimulated lymphocytes was studied in patients with bronchial asthma. Oxatomide alone has almost no effect on lymphocyte activation. Patient's lymphocytes pretreated with 2 to 2000 ng/ml doses of oxatomides for 24 to 48 hours failed to produce Df-induced IL2 responsiveness in a dose-dependent manner. The target cells for oxatomide's suppressive effect were antigen-presenting cells such as macrophages and dendritic cells rather than responder T cells. PPD-induced IL2 responsiveness was also suppressed by the treatment, but the Con A-induced response was not. The results suggest that oxatomide has a slight immunosuppressive capability to block the induction of IL2 responsiveness by Df-stimulated patient's lymphocytes, resulting in the decreased production of such lymphokines as IL2, IL3, IL4, IL5, in a lymphokine cascade of allergic responses, in addition to inhibition of the degranulation and activation of inflammatory cells such as mast cells/basophils and eosinophils.
Yoshizawa
I
I
Department of Pediatrics, Saitama Medical School.
Nakajima
T
T
Kawano
Y
Y
Noma
T
T
D000818:Animals; D000941:Antigens / Q000276:immunology*; D001249:Asthma / Q000276:immunology*; D002478:Cells, Cultured; D003864:Depression, Chemical; D004305:Dose-Response Relationship, Drug; D006634:Histamine H1 Antagonists / Q000494:pharmacology*; D006801:Humans; D007376:Interleukin-2 / Q000096:biosynthesis*; D008214:Lymphocytes / Q000276:immunology*; D008925:Mites / Q000276:immunology*; D010879:Piperazines / Q000494:pharmacology*
D000941:Antigens; D006634:Histamine H1 Antagonists; D007376:Interleukin-2; D010879:Piperazines; C015408:oxatomide